Compare Verisign, Inc. (VRSN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Verisign, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Verisign, Inc. trades at $304.06 (market cap $26.92B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Verisign, Inc. is far larger — about 2.7× State Street SPDR S&P Biotech ETF's market cap, and Verisign, Inc. pays a 1.09% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Verisign, Inc. for 123 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VRSN | XBI | |
|---|---|---|
Market Cap | $26.92B | $10.11B |
Volume | 1,921,402 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $310.00 | $169.55 |
52-Week Low | $211.49 | $104.99 |
Typical Hold Time | 123 Days | 38 Days |
Enterprise Value | $28.23B | — |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VeriSign (VRSN) trades at $305.53, up 3.84% today, with a bullish technical outlook and strong institutional buying. The company reported solid Q2 2026 results with revenue up 6% year-over-year and EPS of $2.38, though it missed expectations slightly. High profitability is evident with a net income margin near 50%, but valuation multiples like P/E of 32.33 are elevated. Recent news includes an antitrust lawsuit and insider selling by the CEO, while major institutions like BlackRock have increased stakes.
The stock offers growth potential from domain registration increases and AI-driven demand, with a consensus price target of $348 implying 14% upside. Risks include regulatory scrutiny from the antitrust case, high debt levels, and premium valuation. Analyst sentiment is positive with 60% buy ratings, but investors should monitor Q3 2026 earnings on October 22 for confirmation of growth trends.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
